Clinical

CHICAGO | Two major ovarian cancer trials demonstrating the benefit of adding bevacizumab to traditional chemotherapy were presented at this year’s ASCO meeting. The first showed the angiogenesis blocker’s ability to extend progression-free survival in recurrent disease. The second suggested initial use of the tumour-starving drug for newly diagnosed cancer may be warranted, particularly in patients with more aggressive disease.

CHICAGO | The aromatase inhibitor exemestane reduces the risk of invasive breast cancer by 65% in high-risk postmenopausal women, according to a large phase III, placebo-controlled trial led and coordinated by Canada’s NCIC Clinical Trials Group.